• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

New York Heart Association classification may be an incomplete predictor of adverse cardiovascular outcomes

byZoya GomesandYuchen Dai
December 21, 2022
in Cardiology, Chronic Disease
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In this secondary analysis of the PARADIGM-HF trial, the association between the New York Heart Association (NYHA) classification and cardiovascular outcomes was ambiguous among 8326 patients.

2. While higher NYHA classification was associated with worse prognosis, NYHA Class I patients with high natriuretic peptides presented higher event rates than patients with low natriuretic peptides from any NYHA class.

Evidence Rating Level: 2 (Good)

Study Rundown: The New York Heart Association (NYHA) classification has widely been accepted as a measure of functional capacity to describe patients with heart failure (HF). Despite the importance of NYHA classification in HF treatment and management, this system is subject to various limitations, such as poor correlation with cardiopulmonary exercise tests. This secondary analysis of the PARADIGM-HF trial sought to assess the association between NYHA class and objective markers of HF, such as N-terminal pro-B-type natriuretic peptide (NT-proBNP) and long-term prognosis. Included patients were all NYHA class II or higher at baseline and were treated with sacubitril-valsartan before randomization. The main exposure was NYHA class at randomization after 6 to 10 weeks of the run-in period. Primary outcomes included cardiovascular (CV) death or first HF hospitalization. A total of 8326 patients with known NYHA classification were included in this study. Of 389 patients in NYHA class I, 58% changed functional class during the first year after randomization. The level of NT-proBNP was found to be a poor discriminator of NYHA classification. Patients classified as NYHA III displayed a distinctively higher rate of CV events, and patients in NYHA class I and II revealed lower event rates. Patients in NYHA class I and II overlapped substantially in NT-proBNP and long-term prognosis. A strength of this study was its large sample size. A limitation is that the subset of NYHA class I patients included in this secondary analysis may not be representative of all NYHA class I patients.

Click to read the study in JAMA Cardiology

Relevant Reading: Implications of the New York Heart Association classification

In-Depth [randomized controlled trial]: This study assessed the patient variation in NYHA classification and analyzed the association between NYHA class, NT-proBNP, and long-term prognosis in the multi-center, double-blind PARADIGM-HF trial. A total of 8326 patients with known NYHA classification at randomization were included. All patients in the PARADIGM-HF trial were NYHA class II or higher at baseline and were treated with sacubitril-valsartan during a 6 to 10-week run-in period. The primary outcomes were CV death or first HF hospitalization. Of the 389 patients in NYHA class I, 228 (58%) changed functional class during the first year after randomization. Additionally, the level of NT-proBNP was found to be a poor discriminator of NYHA class. For NYHA class I vs II, the AUC was 0.51 (95% CI, 0.48-0.54). Patients classified as NYHA I and II revealed lower event rates (NYHA II vs I, HR 1.24; 95% CI, 0.97 – 1.58). Patients classified as NYHA III demonstrated a distinctively higher rate of CV events (NYHA III vs I, hazard ratio [HR], 1.84; 95% CI, 1.44 – 2.37; NYHA III vs II, HR, 1.49; 95% CI, 1.35 – 1.64). Upon stratification by NT-proBNP levels, subgroups with distinctive risk were identified, such that NYHA class I patients with a higher NT-proBNP level (n=175) had a numerically higher event rate than patients presenting with low NT-proBNP levels from any NYHA class (vs class I, HR, 3.43; 95% CI, 2.03 – 5.87; vs class II, HR, 2.12; 95% CI, 1.58 – 2.86; vs class III, HR, 1.37; 95% CI, 1.00 – 1.88).

RELATED REPORTS

Torsemide not associated with significant difference in all-cause mortality over 12 months compared to furosemide – The TRANSFORM-HF randomized clinical trial

Clinical decision-making strategy improves acute heart failure outcomes

Ferric derisomaltose may reduce heart failure-related hospitalizations

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: heart failureNT-proBNPNYHAparadigm hf
Previous Post

Environmental noises are associated with poor self-reported sleep quality

Next Post

#VisualAbstract: Transcatheter aortic valve implantation is associated with reduced rate of structural valve deterioration compared to surgery

RelatedReports

Radiation dose associated with increased heart disease in Hodgkin lymphoma survivors
Cardiology

Torsemide not associated with significant difference in all-cause mortality over 12 months compared to furosemide – The TRANSFORM-HF randomized clinical trial

January 24, 2023
Remote patient monitoring did not reduce heart failure readmissions: The BEAT-HF trial
Cardiology

Clinical decision-making strategy improves acute heart failure outcomes

January 12, 2023
No association found between length of storage for transfused red blood cells and patient mortality
Cardiology

Ferric derisomaltose may reduce heart failure-related hospitalizations

December 27, 2022
Quick Take: Association of African Ancestry with Electrocardiographic Voltage and Concentric Left Ventricular Hypertrophy: The Dallas Heart Study
Cardiology

No known association between PCSK9 gene variants and risk of heart failure

December 22, 2022
Next Post
#VisualAbstract: Transcatheter aortic valve implantation is associated with reduced rate of structural valve deterioration compared to surgery

#VisualAbstract: Transcatheter aortic valve implantation is associated with reduced rate of structural valve deterioration compared to surgery

Neutrophil CD64 index may be superior for screening for pediatric infections in the ICU

#VisualAbstract: Smartphone dispatch of volunteer responders may not increase bystander use of automated external defibrillator in out-of-hospital cardiac arrest

#VisualAbstract: Smartphone dispatch of volunteer responders may not increase bystander use of automated external defibrillator in out-of-hospital cardiac arrest

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Chronic obstructive pulmonary disease associated with worse postoperative outcomes
  • Empagliflozin use is associated with slower progression of chronic kidney disease
  • Diagnostic tool may help identify cerebral palsy regardless of encephalopathy features
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options